- Home
- DLXY vs PULM Comparison
DLXY vs PULM Comparison
Compare DLXY & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DLXY | PULM |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 5.2M |
| IPO Year | 2024 | 2013 |
Fundamental Metrics
Financial Performance| Metric | DLXY | PULM |
|---|---|---|
| Price | $1.76 | $1.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 817.1K | 18.6K |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,910,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $67.27 |
| P/E Ratio | $11.23 | ★ N/A |
| Revenue Growth | N/A | ★ 5069.93 |
| 52 Week Low | $0.34 | $1.16 |
| 52 Week High | $4.25 | $4.98 |
Technical Indicators
Market Signals| Indicator | DLXY | PULM |
|---|---|---|
| Relative Strength Index (RSI) | 54.67 | 50.46 |
| Support Level | $0.39 | $1.41 |
| Resistance Level | $3.20 | $1.82 |
| Average True Range (ATR) | 0.33 | 0.11 |
| MACD | -0.10 | 0.00 |
| Stochastic Oscillator | 10.53 | 51.09 |
Price Performance
Historical ComparisonAbout DLXY Delixy Holdings Limited Ordinary Shares
Delixy Holdings Ltd a holding company. Through its subsidiary, it is principally engaged in the trading of oil-related products, which are broadly categorized into crude oil and oil-based products, including naphtha, motor gasoline, gas oil, fuel oil, asphalt, base oil, and other petrochemicals. These products are traded across multiple countries in Southeast Asia, East Asia, and the Middle East, and the Group has established a presence in the oil trading markets in these countries. The majority of the Group's revenue is generated from the trading of crude oil. Geographically, it derives maximum revenue from its business in East Asia.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).